CDH11 and neoplasm: In contrast to the in vitro experimental results, percutaneously evaluated tumor size was significantly smaller at 4 weeks in xenograft tumors derived from both sh#1 and sh#2 CDH11 KD cells compared with shCtrl cells (Figure 3a,b).